PCA
HAE icon

Pallas Capital Advisors’s Haemonetics HAE Stock Holding History

Pallas Capital Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Buy
+2,832
New +$182K 0.01% 886
2026
Q1 		– Sell
-3,814
Closed -$306K – 916
2025
Q4 		$306K Buy
+3,814
New +$256K 0.01% 672

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pallas Capital Advisors's HAE Position: Q2 2026 in Review

Pallas Capital Advisors opened a new position in Haemonetics (HAE) in Q2 2026: 2,832 shares worth $212K. The stake represents 0.01% of the portfolio and ranks #886 among its holdings. This is a return to the name: Pallas Capital Advisors previously reported a position in HAE as recently as Q4 2025.

Pallas Capital Advisors first reported a position in HAE in Q4 2025 and has held it in 2 quarters since. The position peaked at $306K in Q4 2025. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Pallas Capital Advisors held 2,832 shares of Haemonetics worth $212K as of Q2 2026.
  • Haemonetics was a new Pallas Capital Advisors position in Q2 2026.
  • Haemonetics made up 0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #886 holding.
  • Pallas Capital Advisors first reported a position in Haemonetics in Q4 2025 and has held it in 2 quarters since.
  • Pallas Capital Advisors's Haemonetics position peaked at $306K in Q4 2025.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.